Paclitaxel injection intravenous infusion — Competitive Intelligence Brief

Paclitaxel injection intravenous infusion (Paclitaxel injection intravenous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin Oncology Small molecule

Target snapshot

Paclitaxel injection intravenous infusion (Paclitaxel injection intravenous infusion) — LaNova Medicines Limited. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paclitaxel injection intravenous infusion TARGET	Paclitaxel injection intravenous infusion	LaNova Medicines Limited	phase 3	Taxane; microtubule stabilizer	β-tubulin
ZENTEL and Vitamin A Soft Capsules	ZENTEL and Vitamin A Soft Capsules	Chengdu Maternal and Children's Health Care Hospital	marketed	Anthelmintic + Vitamin supplement	β-tubulin (albendazole component)
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Paclitaxel protein bound	Paclitaxel protein bound	Barts & The London NHS Trust	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Docetaxel or albumin paclitaxel	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

1. Sanofi · 2 drugs in this class
2. Aravive, Inc. · 1 drug in this class
3. Athenex, Inc. · 1 drug in this class
4. Barts & The London NHS Trust · 1 drug in this class
5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
6. Bio-Thera Solutions · 1 drug in this class
7. Dai, Guanghai · 1 drug in this class
8. Fujian Medical University · 1 drug in this class
9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class